The Global Hyperphosphatemia Drugs market has also been witnessing the trend of an increasing number of strategic alliances among vendors. However, side effects caused by the hyperphosphatemia drugs could pose a challenge to the growth of this market, the Global Hyperphosphatemia Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hyperphosphatemia Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Authored by: TechNavio
Published: July 2012
Format: Electronic - PDF by eMail
Number of Pages: #37
Table of Contents
1. Executive Summary
2. Introduction
3. Market Coverage
4. Market Landscape
5. Geographical Segmentation
6. Key Leading Countries
7. Rate of Incidence and Prevalence
8. Vendor Landscape
9. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Sanofi S.A.
15.2 Shire plc.
15.3 Fresenius Medical Care AG & Co. KGaA
16. Other Reports in this Series
List of Exhibits
1. Global Hyperphosphatemia Drugs Market 2011–2015 (US$ million)
2. Global Hyperphosphatemia Drugs Market by Geographical Segmentation 2011
3. Global Hyperphosphatemia Drugs Market by Vendor Segmentation 2011
Companies Mentioned
1. Fresenius Medical Care AG & Co. KGaA
2. Shire plc
3. Sanofi S.A
2. Shire plc
3. Sanofi S.A